Randomized, Double-Blind, Placebo-Controlled Trial Using Lidocaine Patch 5% in Traumatic Rib Fractures

被引:46
|
作者
Ingalls, Nichole K. [1 ]
Horton, Zachary A. [1 ]
Bettendorf, Matthew [2 ]
Frye, Ira [1 ]
Rodriguez, Carlos [1 ]
机构
[1] Michigan State Univ, Grand Rapids Med Educ & Res Ctr, Grand Rapids, MI 49503 USA
[2] Cent Minnesota Surg, Gen & Bariatr Surg, Sartell, MN USA
关键词
LIDODERM; PAIN;
D O I
10.1016/j.jamcollsurg.2009.10.020
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: The lidocaine patch 5% was developed to treat postherpetic neuralgia. Anecdotal experience at our institution suggests the lidocaine patch 5% decreases narcotic usage in patients with traumatic rib fractures. This trial was developed to define the patch's efficacy. STUDY DESIGN: Patients with rib fractures admitted to the trauma service at our Level I trauma center were enrolled and randomized in a 1 to 1 double-blind manner to receive a lidocaine patch 5% or placebo patch. Fifty-eight patients who met the inclusion criteria were enrolled from January 2007 to August 2008. Demographic and clinical information were recorded. The primary outcomes variable was total narcotic use, analyzed using the 1-tailed Mann-Whitney test. The secondary outcomes variables included non-narcotic pain medication, average pain score, pulmonary complications, and length of stay. Significance was defined based on a 1-sided test for the primary outcome and 2-sided tests for other comparisons, at p < 0.05. RESULTS: Thirty-three patients received the lidocaine patch 5% and 25 received the placebo patch. There were no significant differences in age, number of rib fractures, gender, trauma mechanism, preinjury lung disease, smoking history, percent of current smokers, and need for placement of chest tube between the lidocaine patch 5% and placebo groups. There was no difference between the lidocaine patch 5% and placebo groups, respectively, with regard to total IV narcotic usage: median, 0.23 units versus 0.26 units; total oral narcotics: median, 4 units versus 7 units; pain score: 5.6 +/- 0.4 versus 6.0 +/- 0.3 (mean +/- SEM); length of stay: 7.8 +/- 1.1 versus 6.2 +/- 0.7; or percentage of patients with pulmonary complications: 72.7% versus 72.0%. CONCLUSIONS: The lidocaine patch 5% does not significantly improve pain control in polytrauma patients with traumatic rib fractures. (J Am Coll Surg 2010;210:205-209. (C) 2010 by the American College of Surgeons)
引用
收藏
页码:205 / 209
页数:5
相关论文
共 50 条
  • [21] Magnesium sulfate with lidocaine for preventing propofol injection pain: a randomized, double-blind, placebo-controlled trial
    Richard E. Galgon
    Peter Strube
    Jake Heier
    Jeremy Groth
    Sijian Wang
    Kristopher M. Schroeder
    Journal of Anesthesia, 2015, 29 : 206 - 211
  • [22] Lidocaine Pretreatment Reduces the Discomfort of Intranasal Midazolam Administration: A Randomized, Double-blind, Placebo-controlled Trial
    Smith, David
    Cheek, Hugh
    Denson, Brenda
    Pruitt, Christopher M.
    ACADEMIC EMERGENCY MEDICINE, 2017, 24 (02) : 161 - 167
  • [23] A randomized, double-blind, placebo-controlled trial: Paroxetine controlled release in fibromyalgia
    Patkar, AA
    Masand, PS
    Jiang, W
    Krulewicz, S
    Dube, E
    Purcell, C
    McMorran, C
    Peindl, K
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S319 - S320
  • [24] A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
    Turner, R. Scott
    Thomas, Ronald G.
    Craft, Suzanne
    van Dyck, Christopher H.
    Mintzer, Jacobo
    Reynolds, Brigid A.
    Brewer, James B.
    Rissman, Robert A.
    Raman, Rema
    Aisen, Paul S.
    NEUROLOGY, 2015, 85 (16) : 1383 - 1391
  • [25] Lansoprazole in Globus Pharyngeus: Double-Blind, Randomized, Placebo-Controlled Trial
    Dumper, Jaymi
    Mechor, Brad
    Chau, Jason
    Allegretto, Michael
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2008, 37 (05): : 657 - 663
  • [26] Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial
    Levin, B
    Thompson, JLP
    Levy, G
    Mitsumoto, H
    Kaufmann, P
    NEUROLOGY, 2006, 66 (11) : 1786 - 1786
  • [27] Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial
    Khan, AA
    Bilezikian, JP
    Kung, AWC
    Ahmed, MM
    Dubois, SJ
    Ho, AYY
    Schussheim, D
    Rubin, MR
    Shaikh, AM
    Silverberg, SJ
    Standish, TI
    Syed, Z
    Syed, ZA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07): : 3319 - 3325
  • [28] DEXAMETHASONE FOR THE TREATMENT OF DEPRESSION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL
    ARANA, GW
    SANTOS, AB
    LARAIA, MT
    MCLEODBRYANT, S
    BEALE, MD
    RAMES, LJ
    ROBERTS, JM
    DIAS, JK
    MOLLOY, M
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (02): : 265 - 267
  • [29] Donepezil for cancer fatigue: A double-blind, randomized, placebo-controlled trial
    Bruera, Eduardo
    El Osta, Badi
    Valero, Vicente
    Driver, Larry C.
    Pei, Be-Lian
    Shen, Loren
    Poulter, Valerie A.
    Palmer, J. Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3475 - 3481
  • [30] Fluoxetine for depression in diabetes - A randomized double-blind placebo-controlled trial
    Lustman, PJ
    Freedland, KE
    Griffith, LS
    Clouse, RE
    DIABETES CARE, 2000, 23 (05) : 618 - 623